2 recruiting, 1 active not recruiting, 1 completed. 4 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 2, Active not recruiting 1, Completed 1 |
| Phase 1 | 3 | Recruiting 2, Active not recruiting 1 |
Follow LB100: new trials by email Literature Review of LB100 trials Research Report on LB100
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100 Dostarlimab, LB-100 - Ovarian Clear Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 21 | 2023-11-10 | 2026-06-23 |
| Phase I/II of LB-100 Plus Doxorubicin vs. Doxorubicin Alone in First Line of Advanced Soft Tissue Sarcomas LB-100 plus Doxorrubicin, Doxorubicin - Advanced Soft-tissue Sarcoma | Phase 1 / Phase 2 | Active not recruiting | Grupo Espanol de Investigacion en Sarcomas | 152 | 2023-05-29 | 2025-03-21 |
| A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) LB-100 - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Recruiting | Lixte Biotechnology Holdings, Inc. | 47 | 2019-04-01 | 2019-04-08 |
| Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma LB-100 - Astrocytoma, Grades II, III and IV, Glioblastoma Multiforme | Phase 2 | Completed | National Cancer Institute (NCI) | 7 | 2019-01-09 | 2023-11-22 |
Astrocytoma (1) · Brain Neoplasms (1) · Glioblastoma (1) · Glioma (1) · Myelodysplastic Syndromes (1) · Oligodendroglioma (1)
Grupo Espanol de Investigacion en Sarcomas (1) · Lixte Biotechnology Holdings, Inc. (1) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1)
United States (3) · Spain (1)
Amir Jazaeri, M D (1) · Eric C Burton, M.D. (1) · Rami Komrokji, MD (1)